TAS 2022 Toledo Allergy Society Conference

September 14, 2022

It is an exciting time in the field of allergy and immunology. This CME program is designed to allow attendees to continue exploring the Immunology Frontier.  Covered topics include current and emerging treatments in angioedema, immunodeficiency and food allergy.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Toledo Allergy Society (TAS). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Review diagnosis and treatment of different types of angioedema and prioritize steroid sparing treatment options for patients with chronic urticaria
  2. Recommend early food introduction based on current guidelines for prevention of food allergies 
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
Course opens: 
Course expires: 
Event starts: 
09/14/2022 - 7:30am CDT
Event ends: 
09/14/2022 - 4:15pm CDT
Toledo, OH
United States

All identified relevant financial relationships have been mitigated.

Matthew Greenhawt, MD, Speaker: Consultant:  Aquestive; Advisor: Nutricia, DBV, Novartis, Sanofi, Auestive, Prota, Allergy Therapeutics, ALK-Abello, AstraZeneca; Speaker: ImSci, RMSI 
Alan Baptist, MD, Speaker: Speaker: GSK
James Fernandez, MD, Speaker: Speaker: Takeda
Allison Ramsey, MD, Speaker: Speaker: Sanofi/Regeneron, GSK
Matthew Zirwas, MD, Speaker: Speaker: AbbVie, EPI Health, Genentech/Novartis, Leo, Pfizer, Regeneron/Sanofi; Investigator: AbbVie, Amgen, Anaptys Bio, Arcutis, Biocon, Concert, Dermavent, Edess Biotech, EPI Health, Evelo, Galderma, Incyte, Leo, Lilly, Pfizer, Regneron/Sanofi, UCB; Consultant: AbbVie, All Free Clear/Sun, Arcutis, Bausch Health, Cara, EPI Health, Fit Bit, Galderma, Incyte, Jannsen, Leo, Level X, Lilly, LUUM, Oculus, Pfizer, Peloton, Regeneron/Sanofi, Trevi; Speaker: Genentech/Novartis, Leo, Regenron/Sanofi; Advisor: Vial; Part Owner: AsepticMD

The following have no relevant financial relationships to disclose:
Svetlana Kriegel, MD, Planner
M. Razi Rafeeq, MD, Planner
Tammy Guastella, Planner
Rajan Ravikumar, MD, Speaker
Jenny Lee, MD, Speaker
Sara Ellingwood, MD, Speaker
Kelly O’Shea, MD, Speaker
Mariel Benjamin, MD, Speaker
Tim Chew, MD, Speaker

Available Credit

  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
Please login or create an account to take this course.